Elite Pharmaceutical Technology Secures Nearly RMB 100 Million Series B Financing to Advance Oral Complex Drug Delivery Platforms

Recently,Saile Pharmaceutical Technology (Shanghai) Co., Ltd. (“Saile Pharma”) Announces Completion of Nearly RMB 100 Million in Series B Financing, it is reported that this round of investment was led byAnhui INNOVAL CAPITAL Led the Investment，Hefei Industrial Investment Capital、Hefei Innovation InvestmentThe funds raised will be primarily used to support Saile Pharmaceutical’s R&D and clinical activities, as well as the construction of new production facilities. Cuiwei Investment served as the exclusive financial advisor for this round of financing.

Saile Pharmaceutical, founded in the United States, is a platform-based company dedicated to the research and development of novel drug formulation technologies, leveraging advanced drug delivery systems and pharmaceutical manufacturing processes.The company has established a series of oral complex sustained- and controlled-release technology platforms centered on osmotic pump-based sustained- and controlled-release technologies.The pipeline primarily focuses on drugs for chronic diseases in the fields of cardiovascular, endocrine, and autoimmune disorders. Through formulation innovation, we aim to enhance clinical efficacy and reduce adverse reactions, thereby better meeting clinical needs.The Company has more than 10 products under development via the 505(b)(2) and ANDA pathways, with certain products already having received FDA marketing approval, while domestic filings are also in progress.

Dr. Tian Wu, Founder of Saile Pharmaceutical, with over twenty years of experience in pharmaceutical formulation research, process development, and management. Having previously worked at companies such as Sage, Mutual, Amgen, and Alza, he/she has overseen the R&D and production of multiple drug products (including several complex sustained- and controlled-release formulations) that have been successfully marketed. The core team members of Saile all possess experience in manufacturing, GMP management, and regulatory submission within multinational pharmaceutical companies.

Founder, Dr. Tian Wustated: “We extend our gratitude to both new and existing shareholders for their trust and strong support of Saile Pharmaceutical during this period of adjustment in the biopharmaceutical industry. This round of financing will further facilitate the continuous R&D and clinical advancement of our new product candidates, as well as fund the construction of a new production facility. Upon completion, the new facility will significantly enhance the regulatory submission efficiency for Saile’s independently developed products, while reducing production costs without compromising manufacturing capacity.”Saile Pharmaceutical will continue to leverage its expertise and competitive advantages, adhering to its strategic focus on developing complex sustained- and controlled-release formulations with clinical benefits. By accelerating clinical development and continuously reducing production costs, the company aims to provide affordable, high-quality products with proven clinical advantages to chronic disease patients both in China and abroad at the earliest possible time.”

Liu Lu, Partner at INNOVAL CAPITALstated: “We are optimistic about Saile Pharmaceutical’s project initiation strategy and industrialization capabilities. We also hope to leverage the policy advantages of Anhui Province’s pharmaceutical industry to support Saile Pharmaceutical in advancing its clinical research, as well as the sustained development of manufacturing and industrialization for complex sustained- and controlled-release formulations, thereby enabling high-quality products with clinical advantages to benefit patients at an earlier stage. We look forward to our joint efforts in supporting the efficient growth of Saile Pharmaceutical.”

INNOVAL CAPITAL, established in January 2018, is a market-oriented equity investment fund management company under Anhui Investment Group. Focusing on key industries such as big health, TMT, intelligent equipment, and new materials, INNOVAL CAPITAL has built a full-lifecycle fund cluster spanning angel investing, venture capital (VC), private equity (PE), and mergers and acquisitions (M&A). To date, it manages 21 funds with assets under management exceeding RMB 8.7 billion. In the big health sector, its investment portfolio includes Bloomage Biotechnology, Yifan Pharmaceutical, Honghe Renai Medical, Zhongke Tuoran, Shangde Yaoyuan, Lianchuang Biology, Heyi Pharmaceutical, Qihao Medical, Inno Medical, Happiness Factory, and Xuankai Biology.

Hefei Industrial Investment Capital was established and began operations in December 2019. As a specialized investment platform built by Hefei Industrial Investment Group, it has constructed a core business system centered on fund-of-funds management, industrial fund operations, and investment in major projects. Its investment portfolio covers frontier sectors such as integrated circuits, new energy vehicles, intelligent manufacturing, and biopharmaceuticals. To date, it has supported a total of 223 projects, with cumulative investments amounting to RMB 24.3793 billion. The company has played a key role in participating in two national-level funds: the National Integrated Circuit Industry Investment Fund Phase II and the National Advanced Manufacturing Industry Investment Fund Phase II. In the biopharmaceutical sector, it has invested in projects including Haisen Biology, Tiangang Medical, Hefei Qihao, Haina Technology, Kangnuo Pharmaceutical, Jingze Biology, Ruishi Technology, Xingmou Biology, and Afana.

The Feixi County Angel Investment Fund is a policy-oriented support fund jointly established by Feixi County Urban and Rural Construction Investment Co., Ltd. as the lead sponsor, together with Hefei Innovation Technology Venture Capital Co., Ltd., Hefei Angel Investment Fund Co., Ltd., and Hefei Guoyao Capital Investment Management Co., Ltd. With a total capital size of RMB 80.1 million (Phase I and Phase II), the fund primarily invests in early-stage enterprises registered in Feixi County that align with the county’s industrial development policies and demonstrate strong growth potential and development prospects.

As the first county-level angel investment fund in Anhui Province, the Feixi County Angel Fund has been committed to identifying and reserving high-quality projects. It invests in small and medium-sized technology enterprises within the region and its surroundings that feature high technological content, promising market prospects, innovative business models, and strong growth potential. While leveraging policy-funded support, the fund strives to maximize the effectiveness of its assistance.

Cuiwei Investment is a new type of industrial investment bank specializing in equity financing for growth-stage biopharmaceutical companies. It currently focuses on capital solutions for pre-IPO innovative drug enterprises. By integrating the strengths of investment banking, startup incubation, and management consulting, Cuiwei develops tailored solutions based on each company’s specific needs to achieve precise matching and high success rates.

Building on our team’s long-standing expertise in the biopharmaceutical sector, we have established extensive connections with China’s most active and professional angel funds, venture capital firms, private equity funds, and strategic industry investors.

Cuiwei Investment is committed to advancing human health and medical progress, with the ultimate mission of enhancing humanity’s access to a better future through its investments.